195 related articles for article (PubMed ID: 31725814)
1. Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer.
Sandblom V; Spetz J; Shubbar E; Montelius M; Ståhl I; Swanpalmer J; Nilsson O; Forssell-Aronsson E
PLoS One; 2019; 14(11):e0225260. PubMed ID: 31725814
[TBL] [Abstract][Full Text] [Related]
2. Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.
Sandblom V; Spetz J; Shubbar E; Montelius M; Ståhl I; Swanpalmer J; Nilsson O; Forssell-Aronsson E
PLoS One; 2020; 15(5):e0233720. PubMed ID: 32459817
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2.
Dalmo J; Rudqvist N; Spetz J; Laverman P; Nilsson O; Ahlman H; Forssell-Aronsson E
Oncol Rep; 2012 Jan; 27(1):174-81. PubMed ID: 21993546
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Hofving T; Sandblom V; Arvidsson Y; Shubbar E; Altiparmak G; Swanpalmer J; Almobarak B; Elf AK; Johanson V; Elias E; Kristiansson E; Forssell-Aronsson E; Nilsson O
Endocr Relat Cancer; 2019 Apr; 26(4):437-449. PubMed ID: 30730850
[TBL] [Abstract][Full Text] [Related]
5. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
6. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.
Ezziddin S; Reichmann K; Yong-Hing C; Damm M; Risse J; Ahmadzadehfar H; Logvinski T; Guhlke S; Biersack HJ; Sabet A
Nuklearmedizin; 2013; 52(5):170-7. PubMed ID: 23963021
[TBL] [Abstract][Full Text] [Related]
7. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
Hubble D; Kong G; Michael M; Johnson V; Ramdave S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1869-75. PubMed ID: 20445977
[TBL] [Abstract][Full Text] [Related]
8. Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.
Ahn HY; Chae JE; Moon H; Noh J; Park YJ; Kim SG
Endocrinol Metab (Seoul); 2020 Dec; 35(4):811-819. PubMed ID: 33212545
[TBL] [Abstract][Full Text] [Related]
9. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
Kwekkeboom DJ; Bakker WH; Kooij PP; Konijnenberg MW; Srinivasan A; Erion JL; Schmidt MA; Bugaj JL; de Jong M; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1319-25. PubMed ID: 11585290
[TBL] [Abstract][Full Text] [Related]
10. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
van Essen M; Krenning EP; Kam BL; de Herder WW; van Aken MO; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):743-8. PubMed ID: 18188559
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 May; 40(5):408-12. PubMed ID: 25674858
[TBL] [Abstract][Full Text] [Related]
12. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
13. Combination chemoradiotherapy with gemcitabine: potential applications.
Choy H
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):20-5. PubMed ID: 10960941
[TBL] [Abstract][Full Text] [Related]
14. Maximizing therapeutic gain with gemcitabine and fractionated radiation.
Mason KA; Milas L; Hunter NR; Elshaikh M; Buchmiller L; Kishi K; Hittelman K; Ang KK
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1125-35. PubMed ID: 10421547
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.
Fechner G; Perabo FG; Schmidt DH; Haase L; Ludwig E; Schueller H; Blatter J; Mller SC; Albers P
Urology; 2003 Feb; 61(2):468-73. PubMed ID: 12597983
[TBL] [Abstract][Full Text] [Related]
17. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
Beukhof CM; Brabander T; van Nederveen FH; van Velthuysen MF; de Rijke YB; Hofland LJ; Franssen GJH; Fröberg LAC; Kam BLR; Visser WE; de Herder WW; Peeters RP
BMC Cancer; 2019 Apr; 19(1):325. PubMed ID: 30953466
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of tumor radioresponse in vivo by gemcitabine.
Milas L; Fujii T; Hunter N; Elshaikh M; Mason K; Plunkett W; Ang KK; Hittelman W
Cancer Res; 1999 Jan; 59(1):107-14. PubMed ID: 9892194
[TBL] [Abstract][Full Text] [Related]
19. [Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination].
Azria D; Jacot W; Prost P; Culine S; Ychou M; Lemanski C; Dubois JB
Bull Cancer; 2002 Apr; 89(4):369-79. PubMed ID: 12016038
[TBL] [Abstract][Full Text] [Related]
20. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index.
Crane CH; Wolff RA; Abbruzzese JL; Evans DB; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Lahoti S; Vauthey JN; Janjan NA
Semin Oncol; 2001 Jun; 28(3 Suppl 10):25-33. PubMed ID: 11510031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]